Document Detail

The role of Angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies.
MedLine Citation:
PMID:  20860414     Owner:  NLM     Status:  MEDLINE    
Hypertension remains a significant health problem, affecting approximately 30% of the US population. Of these, only 36.8% have BP controlled to recommended levels of <140/90 mmHg for uncomplicated hypertension and <130/80 mmHg for patients with diabetes mellitus or renal disease. For those with uncontrolled hypertension, the risk of diabetes, renal disease, stroke, and cardiovascular disease is increased. Therapeutic options for the treatment of hypertension include several major classes of drugs: diuretics, β-adrenoceptor antagonists (β-blockers), ACE inhibitors, angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]), renin inhibitors, calcium channel blockers, and central sympatholytics, alone or in combination. Guidelines recommend thiazide diuretics as preferred first-line monotherapy. However, only 50% of patients will respond adequately to this therapy and the rest will require two or more antihypertensive agents to achieve BP goals. Clinical evidence demonstrates that some drugs have advantages when used in combination rather than as monotherapy. Drugs that block the renin-angiotensin-aldosterone system not only provide BP control but may also provide vascular protection and are metabolically neutral. This is a concise review of the safety and efficacy of ARBs in combination with amlodipine for the treatment of hypertension, with focus on the telmisartan-amlodipine combination. A MEDLINE search of the English literature from 2006 to 2009 of amlodipine in combination with ARBs revealed six publications, which are included in this review.
Steven G Chrysant
Related Documents :
9663914 - Blood pressure screening, management and control in england: results from the health su...
1053494 - Helping the hypertensive patient to help himself.
20172984 - Clevidipine: a new intravenous option for the management of acute hypertension.
1381794 - Determining hypertensive end-organ damage in trials: a review of current methodologies ...
7867244 - The effect of heat shock on immediate post-preservation lung function.
19503454 - Combining a difference-frequency source with an off-axis high-finesse cavity for trace-...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  American journal of cardiovascular drugs : drugs, devices, and other interventions     Volume:  10     ISSN:  1175-3277     ISO Abbreviation:  Am J Cardiovasc Drugs     Publication Date:  2010  
Date Detail:
Created Date:  2010-09-23     Completed Date:  2011-01-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100967755     Medline TA:  Am J Cardiovasc Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  315-20     Citation Subset:  IM    
Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma School of Medicine, Oklahoma City, Oklahoma, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin Receptor Antagonists / administration & dosage*
Calcium Channel Blockers / administration & dosage*
Drug Therapy, Combination
Hypertension / drug therapy*
Reg. No./Substance:
0/Angiotensin Receptor Antagonists; 0/Calcium Channel Blockers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hyperchol...
Next Document:  Cardiovascular risk-benefit profile of sibutramine.